Glenview Trust Co increased its position in shares of Celgene Corporation (NASDAQ:CELG) by 5.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 70,484 shares of the biopharmaceutical company’s stock after buying an additional 3,628 shares during the period. Glenview Trust Co’s holdings in Celgene Corporation were worth $8,771,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Motco increased its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the first quarter valued at $118,000. Oakworth Capital Inc. increased its position in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the period. Finally, Reilly Financial Advisors LLC increased its position in shares of Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 161 shares during the period. Institutional investors and hedge funds own 79.43% of the company’s stock.

Celgene Corporation (CELG) traded down 0.16% during mid-day trading on Tuesday, reaching $131.44. The company’s stock had a trading volume of 376,649 shares. The stock’s 50 day moving average is $133.39 and its 200 day moving average is $125.39. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The firm has a market cap of $102.83 billion, a PE ratio of 40.71 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.44 earnings per share. On average, analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.

WARNING: “Glenview Trust Co Has $8.77 Million Position in Celgene Corporation (CELG)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/29/glenview-trust-co-has-8-77-million-position-in-celgene-corporation-celg.html.

Several research analysts recently weighed in on CELG shares. BTIG Research restated a “buy” rating and set a $138.00 target price on shares of Celgene Corporation in a research note on Wednesday, May 24th. Argus upgraded Celgene Corporation from a “hold” rating to a “buy” rating and boosted their target price for the stock from $96.93 to $160.00 in a research note on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and set a $160.00 target price on shares of Celgene Corporation in a research note on Tuesday, July 11th. Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a research note on Monday. Finally, Zacks Investment Research downgraded Celgene Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $147.38.

In other Celgene Corporation news, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the transaction, the insider now owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 253,761 shares of company stock worth $33,792,445. 0.95% of the stock is owned by company insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.